Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Bitcoin Well (V.BTCW) Reports Q1 2024 Financial Results (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aslan Pharmaceuticals Ltd ASLN

Healthcare Biotechnology
ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The Company's portfolio is led by eblasakimab (ASLAN004), a potential human monoclonal antibody that binds to the IL-13 receptor a1 subunit (IL-13Ra1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis, such as redness... see more

Recent & Breaking News (NDAQ:ASLN)

Aslan Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares

GlobeNewswire December 2, 2019

ASLAN Pharmaceuticals Reports Positive Preliminary Data From Proof-of-Concept Study for ASLAN004 Targeting Atopic Dermatitis

GlobeNewswire December 2, 2019

ASLAN Pharmaceuticals Announces Publication of Preclinical Data on ASLAN003 in AML in Haematologica Journal

GlobeNewswire November 22, 2019

ASLAN Pharmaceuticals Announces Topline Results From TreeTopp Global Pivotal Study of Varlitinib in Biliary Tract Cancer

GlobeNewswire November 11, 2019

ASLAN Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

GlobeNewswire October 31, 2019

ASLAN Pharmaceuticals Enrolls First Patient in Proof-of-Concept Study for ASLAN004 Targeting Atopic Dermatitis

GlobeNewswire October 22, 2019

ASLAN Pharmaceuticals Announces Closing of US$3 Million Loan Facility

GlobeNewswire October 18, 2019

New Data Presented on ASLAN's varlitinib at ESMO 2019

GlobeNewswire October 2, 2019

ASLAN Pharmaceuticals and Bukwang Pharmaceutical Establish a Joint Venture, JAGUAHR Therapeutics, to Develop Novel Immuno-Oncology Therapies

GlobeNewswire September 30, 2019

ASLAN Pharmaceuticals Presents Late-Breaking Data From Phase 2 Study in China Testing Varlitinib in Second Line Biliary Tract Cancer at CSCO

GlobeNewswire September 19, 2019

Abstract on ASLAN Pharmaceuticals' Varlitinib Accepted for Poster Presentation at ESMO Asia Congress 2019

GlobeNewswire September 10, 2019

New Data From Aslan's Study of Varlitinib in China Accepted as Late-Breaking Oral Presentation at 2019 CSCO Annual Meeting

GlobeNewswire August 27, 2019

ASLAN Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update

GlobeNewswire August 13, 2019

ASLAN Pharmaceuticals to Present New Data on Varlitinib at European Society for Medical Oncology Congress

GlobeNewswire July 31, 2019

ASLAN Pharmaceuticals Names Industry Veteran and Current Board Member Andrew Howden to Additional Role of Chairman

GlobeNewswire July 26, 2019

ASLAN Pharmaceuticals Completes Phase 1 Study for ASLAN004 Targeting Atopic Dermatitis

GlobeNewswire June 4, 2019

ASLAN Pharmaceuticals Acquires Full Global Commercial Rights for ASLAN004 From CSL

GlobeNewswire May 31, 2019

ASLAN Pharmaceuticals' Varlitinib Selected by Leading Korean Gastric Cancer Group for Study in Second-Line Gastric Cancer

GlobeNewswire May 10, 2019

ASLAN Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update

GlobeNewswire April 29, 2019

ASLAN Pharmaceuticals to Present Positive varlitinib Data in First-Line Biliary Tract Cancer in Combination With Chemotherapy at ASCO GI

GlobeNewswire January 14, 2019